Glioblastoma (GBM) has been recognized as a clinical and pathologic entity for more than a
century. Throughout its history, its cells of origin have been in question. Its behavior is
aggressive and despite decades of effort, median survival is just beginning to improve.
Surgical techniques and radiotherapy schemas continue to be refined, but the most recent
progress has been achieved through improved medical therapies. These are the result of
both pharmacological advances and a deeper understanding of the biological …